{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:26:24Z","timestamp":1792743984013,"version":"4.5.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Carcinosarcomas (CSs) of the endometrium are biphasic malignancies, composed of high-grade carcinomatous and sarcomatous components. Surgical stage and pathologic characteristics are the most important prognostic findings, with a 5-yr survival of 15% to 30% in advance stage disease. Folate receptor alpha (FRA) overexpression has been observed in endometrial carcinomas and not yet studied in CSs. This study evaluates semiquantitative expression of FRA in both carcinomatous and sarcomatous components of CSs on whole tissue sections. Immunohistochemistry for FRA expression was performed and extent and intensity of staining were recorded for each case for both histologic components. A total of 46 cases were stained for FRA. The majority of these (40\/46, 87%) showed FRA staining at variable intensity in the carcinomatous component, stronger in serous carcinomas and high-grade endometrioid, while only a small subset of tumors demonstrated weak staining in the sarcomatous component (2\/46, 4.35%). CS is known to be associated with poor prognosis and adjuvant therapy is recommended even in low stage disease. Serous and high-grade endometrioid carcinomas are the most common carcinomatous components of CSs and are known to show consistently high FRA expression. Folate plays a role in tumor cell migration and loss of cellular adhesion, which are key steps in epithelial-mesenchymal transition, the process by which CS develops from carcinoma cells. Our study shows expression of FRA in the carcinomatous component of almost all CS cases (87%), further favoring FRA as a target for adjuvant treatment. While expression of FRA in the sarcomatous component was rarely observed, the carcinomatous component being associated with metastatic potential underscores the importance of anti-FRA therapy for systemic disease control.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000736","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T13:32:18Z","timestamp":1608039138000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy"],"prefix":"10.1097","volume":"40","author":[{"given":"Krisztina Z.","family":"Hanley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira R.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ygyno.2005.09.017","article-title":"Clinical features and outcomes of uterine and ovarian carcinosarcoma","volume":"100","author":"Jonson","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181dc8292","article-title":"Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes","volume":"20","author":"Garg","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0301-2115(98)00166-3","article-title":"Carcinosarcoma, endometrial intraepithelial carcinoma and endometriosis after tamoxifen therapy in breast cancer","volume":"82","author":"Friedrich","year":"1999","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1525-1438.1995.05040310.x","article-title":"Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?","volume":"5","author":"Evans","year":"1995","journal-title":"Int J Gynecol Cancer"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ygyno.2006.05.039","article-title":"Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers","volume":"103","author":"Pothuri","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/1097-0142(197809)42:3<1152::AID-CNCR2820420319>3.0.CO;2-L","article-title":"Uterine sarcomas: natural history, treatment and prognosis","volume":"42","author":"Salazar","year":"1978","journal-title":"Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/ijgc-00009577-200211000-00001","article-title":"Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas","volume":"12","author":"McCluggage","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"12238","DOI":"10.1073\/pnas.1614120113","article-title":"Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition","volume":"113","author":"Zhao","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-20250802","first-page":"114","article-title":"Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity","volume":"60","author":"Fujii","year":"2000","journal-title":"Cancer Res"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(20000615)88:12<2782::AID-CNCR17>3.0.CO;2-K","article-title":"Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus","volume":"88","author":"Yamada","year":"2000","journal-title":"Cancer"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/gyno.1997.4629","article-title":"Uterine carcinosarcomas: incidence and trends in management and survival","volume":"65","author":"Arrastia","year":"1997","journal-title":"Gynecol Oncol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0360-3016(03)01561-X","article-title":"Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome","volume":"58","author":"Callister","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2018.10.034","article-title":"Prognostic factors impacting survival in early stage uterine carcinosarcoma","volume":"152","author":"Kurnit","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"suppl","key":"R14-20250802","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study","volume":"71","author":"Major","year":"1993","journal-title":"Cancer"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.06.020","article-title":"A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma","volume":"127","author":"Cantrell","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"17442","DOI":"10.18632\/oncotarget.7856","article-title":"Concordance of folate receptor-alpha expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients","volume":"7","author":"Boogerd","year":"2016","journal-title":"Oncotarget"},{"key":"R17-20250802","first-page":"4989","article-title":"A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer","volume":"9","author":"Shi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F","article-title":"Overexpression of folate binding protein in ovarian cancers","volume":"74","author":"Toffoli","year":"1997","journal-title":"Int J Cancer"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2012-0176-OA","article-title":"Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents","volume":"137","author":"Cagle","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1245\/s10434-007-9755-3","article-title":"Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers","volume":"15","author":"Iwakiri","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"414","DOI":"10.18632\/oncotarget.519","article-title":"Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance","volume":"3","author":"O\u2019Shannessy","year":"2012","journal-title":"Oncotarget"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"e0122209","DOI":"10.1371\/journal.pone.0122209","article-title":"Folate receptor-alpha (FOLR1) expression and function in triple negative tumors","volume":"10","author":"Necela","year":"2015","journal-title":"PLoS One"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/ijc.29937","article-title":"Serum folate receptor alpha as a biomarker for ovarian cancer: implications for diagnosis, prognosis and predicting its local tumor expression","volume":"138","author":"Kurosaki","year":"2016","journal-title":"Int J Cancer"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/PAI.0000000000000476","article-title":"Folate receptor alpha expression in platinum resistant\/refractory ovarian carcinomas and primary endocervical adenocarcinomas","volume":"26","author":"Rubinsak","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"R26-20250802","first-page":"5633","article-title":"Folate receptor alpha expression and significance in endometrioid endometrium carcinoma and endometrial hyperplasia","volume":"8","author":"Senol","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"R27-20250802","first-page":"775","article-title":"Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix","volume":"8","author":"Wu","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clbc.2017.03.007","article-title":"Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast cancer","volume":"17","author":"Ginter","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ygyno.2007.09.003","article-title":"Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum","volume":"108","author":"Cicin","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(19860101)57:1<155::AID-CNCR2820570131>3.0.CO;2-C","article-title":"Patterns of recurrence in malignant mixed mullerian tumor of the uterus","volume":"57","author":"Spanos","year":"1986","journal-title":"Cancer"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/PGP.0b013e31823bb24d","article-title":"HER2\/neu as a potential target for immunotherapy in gynecologic carcinosarcomas","volume":"31","author":"Guzzo","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ygyno.2006.11.001","article-title":"Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets","volume":"105","author":"Cimbaluk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41379-019-0358-x","article-title":"HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy","volume":"33","author":"Rottmann","year":"2020","journal-title":"Mod Pathol"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/ijgc-00009577-200601000-00067","article-title":"Expression and amplification of HER-2\/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?","volume":"16","author":"Raspollini","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"15878","DOI":"10.18632\/oncotarget.15032","article-title":"Identification of distinct molecular subtypes of uterine carcinosarcoma","volume":"8","author":"An","year":"2017","journal-title":"Oncotarget"},{"key":"R37-20250802","first-page":"309","article-title":"Novel targeted therapies in ovarian and uterine carcinosarcomas","volume":"25","author":"Han","year":"2018","journal-title":"Discov Med"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-007-9048-0","article-title":"The folate receptor: what does it promise in tissue-targeted therapeutics?","volume":"26","author":"Salazar","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1002\/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S","article-title":"Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications","volume":"73","author":"Ross","year":"1994","journal-title":"Cancer"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/srep00980","article-title":"Nuclear localization of folate receptor alpha: a new role as a transcription factor","volume":"2","author":"Boshnjaku","year":"2012","journal-title":"Sci Rep"},{"issue":"pt 2","key":"R41-20250802","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1006\/gyno.2002.6705","article-title":"A step further in understanding the biology of the folate receptor in ovarian carcinoma","volume":"88","author":"Bagnoli","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/MCB.00315-09","article-title":"The absence of caveolin-1 increases proliferation and anchorage-independent growth by a Rac-dependent, Erk-independent mechanism","volume":"29","author":"Cerezo","year":"2009","journal-title":"Mol Cell Biol"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0046-8177(97)90007-1","article-title":"Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases","volume":"28","author":"Darai","year":"1997","journal-title":"Hum Pathol"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/sj.gt.3301962","article-title":"Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies","volume":"10","author":"Figini","year":"2003","journal-title":"Gene Ther"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13402-011-0052-6","article-title":"The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer","volume":"35","author":"Crane","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","article-title":"Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy","volume":"130","author":"Despierre","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.molonc.2011.11.010","article-title":"Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response","volume":"6","author":"Chen","year":"2012","journal-title":"Mol Oncol"},{"key":"R48-20250802","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1067\/mtc.2001.111176","article-title":"The alpha folate receptor is highly activated in malignant pleural mesothelioma","volume":"121","author":"Bueno","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1158\/1078-0432.CCR-18-0652","article-title":"Anti-folate receptor alpha-directed antibody therapies restrict the growth of triple-negative breast cancer","volume":"24","author":"Cheung","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ygyno.2007.05.018","article-title":"Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas","volume":"107","author":"Allard","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R51-20250802","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J Clin Oncol"},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1758834015584763","article-title":"Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors","volume":"7","author":"Vergote","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"R55-20250802","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(07)70142-0","article-title":"Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer","volume":"8","author":"Hernando","year":"2007","journal-title":"Lancet Oncol"},{"issue":"pt 1","key":"R56-20250802","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:05:34Z","timestamp":1754161534000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000736","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,14]]}}}